First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations.
BloodSep 17, 2026
Michael Wang, Marc Hoffmann, Tomasz Wrobel et al.
✦ AI-curated · Sources linked
In 30 seconds
The phase 3 SYMPATICO study evaluated the efficacy of first-line ibrutinib plus venetoclax in 78 patients with nonblastoid mantle cell lymphoma, specifically those aged ≥65 years or with TP53 mutations. The study found a complete response rate of 69% and a median progression-free survival of 40.2 months, indicating promising outcomes for this patient population.
Key findings
- Complete response rate was 69% (95% CI, 58-79) in the overall cohort.
- Median progression-free survival was 40.2 months (95% CI, 29.4 to NE).
- 3-year overall survival rate was 79% (95% CI, 68-86) with median overall survival not reached.
- In patients aged ≥65 years without TP53 mutations, the complete response rate was 76%.
Why it matters
This study highlights the potential of combining ibrutinib and venetoclax as an effective first-line treatment for older patients or those with specific genetic mutations, addressing a critical need in managing nonblastoid mantle cell lymphoma.